menu
    • menu

    Company profile for Chinook Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Chinook Therapeutics (Nasdaq: KDNY) is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular...
    Chinook Therapeutics (Nasdaq: KDNY) is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Chinook TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    400 Fairview Ave North, 9th Floor Seattle, WA 98109
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.chinooktx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/chinook-therapeutics-inc/about/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ChinookTx?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    5 People Accused of Insider Trading Tied to Novartis Buy
    5 People Accused of Insider Trading Tied to Novartis Buy

    27 May 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/5-people-charged-600k-insider-trading-scheme-tied-novartis-chinook-acquisition

    FIERCE BIOTECH
    27 May 2025
    Share Share
    Novartis and Versant Partner to Form Kidney Disease Biotech
    Novartis and Versant Partner to Form Kidney Disease Biotech

    23 Aug 2024

    // BIOSPACE

    https://www.biospace.com/business/novartis-versant-launch-rna-kidney-medicines-focused-borealis

    BIOSPACE
    23 Aug 2024
    Share Share
    Novartis Completes Acquisition of Chinook Therapeutics
    Novartis Completes Acquisition of Chinook Therapeutics

    11 Aug 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/08/11/2723695/0/en/Novartis-Completes-Acquisition-of-Chinook-Therapeutics.html

    GLOBENEWSWIRE
    11 Aug 2023
    Share Share
    Chinook Announces First Patient Enrolled in Phase 3 BEYOND Study of Zigakibart
    Chinook Announces First Patient Enrolled in Phase 3 BEYOND Study of Zigakibart

    28 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/28/2713095/35377/en/Chinook-Therapeutics-Announces-First-Patient-Enrolled-in-Pivotal-Phase-3-BEYOND-Study-of-Zigakibart-BION-1301-for-Patients-with-IgA-Nephropathy.html

    GLOBENEWSWIRE
    28 Jul 2023
    Share Share
    Chinook Therapeutics Presents Data from CHK-336 Ph1 Trial in Healthy Volunteers
    Chinook Therapeutics Presents Data from CHK-336 Ph1 Trial in Healthy Volunteers

    17 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/17/2689976/35377/en/Chinook-Therapeutics-Presents-Data-from-CHK-336-Phase-1-Trial-in-Healthy-Volunteers-and-New-Insights-into-the-Role-of-Failed-Repair-in-Chronic-Kidney-Disease-at-the-60th-European-R.html

    GLOBENEWSWIRE
    17 Jun 2023
    Share Share
    Chinook to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial
    Chinook to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial

    12 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/12/2686669/35377/en/Chinook-Therapeutics-to-Present-Updated-Data-from-Zigakibart-BION-1301-Phase-1-2-Trial-in-Patients-with-IgA-Nephropathy-IgAN-at-the-60th-European-Renal-Association-ERA-Congress.html

    GLOBENEWSWIRE
    12 Jun 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search